1. What is it?
Thymosin alpha-1 contains 28 amino acids and occurs naturally in the body. Thymalfasin is its synthetic form. A brand name such as Zadaxin identifies a particular product. Do not confuse this substance with Thymalin, a mixture of thymus-derived peptides, or thymosin beta-4. Similar names do not mean shared effects, identical studies or interchangeable products. [121]
2. Why do people turn to it?
Thymosin alpha-1 attracts interest as possible immune support, especially during infections. It has also been studied in chronic viral diseases, alongside some cancer treatments and in sepsis. These are separate uses requiring their own evidence. Sepsis involves a disrupted immune response in severely ill patients. It is not comparable to frequent colds in healthy people or post-exercise recovery. Intensive-care findings cannot be extended to those goals. [121] [120]
3. How does it work?
Thymosin alpha-1 is being studied as a substance that alters the immune system's response. Sepsis studies have assessed, among other things, markers on the surface of cells that help recognise threats and trigger a defence response. Such measurements indicate biological activity, but do not yet answer the most important question: does the patient recover faster and have a better chance of survival? Immunity needs appropriate regulation; increasing one selected measurement is not always a beneficial aim. [120] [119]
4. What do studies actually show?
The ETASS study, published in 2013, enrolled 361 people with severe sepsis. Its findings were considered a reason for further trials. The larger TESTS study then enrolled 1,106 adults at 22 centres in China. The publication of 15 January 2025 found no clear evidence of fewer deaths within 28 days. This result matters more than an isolated favourable change in an immune marker. [120] [119]
5. What do we still not know?
All thymosin alpha-1 publications cannot be combined into one body of proof for immunity. They differ in illnesses, additional treatment, participants' condition and outcomes measured. Some older papers involve small groups or inadequately described methods. Conversely, no clear benefit in sepsis does not rule out every future use. It does provide an important finding for that particular claim which should not be overlooked. [120] [119] [121]
6. What are the risks?
The TESTS trial found no clear difference in the safety events assessed. This does not establish the safety of years of use in healthy people or of every available product. The FDA raised concerns about possible immune reactions, particularly to products containing molecule clusters or impurities. Risk assessment should cover the peptide, the quality of the specific formulation and the recipient's health. [119] [121]
7. Is it an approved medicine?
In its assessment of thymosin alpha-1, the FDA stated that it had not approved a medicine containing the substance. The document also describes products available in other countries. This is an important distinction: use in one healthcare system does not mean FDA approval or EU-wide authorisation. This profile does not attribute an approved indication for rejuvenating immunity to thymosin alpha-1. Pharmacy compounding procedures do not replace an assessment of effectiveness for a particular use. [121]
8. What is new in research?
The most important more recent paper in this overview is the 2025 TESTS trial. It is large, involves humans and measures an outcome that matters to patients rather than only a laboratory cell response. Its primary result did not confirm the expected survival benefit. Further analyses of selected subgroups can generate hypotheses, but should not replace the whole-trial result. Knowledge as of 3 November 2026 therefore calls for more cautious promises, rather than broader marketing. [119]
Where does this information come from?
References link to the publications and documents used. Each source includes its material type and what was reviewed; findings concern the substance, form and study population described.
Show sources and how they were checked
- The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
Multicentre randomised phase 3 human trial; 15 January 2025; PubMed abstract reviewed · DOI: 10.1136/bmj-2024-082583. Accessed: 3 November 2026.
- FDA Briefing Document: Thymosin Alpha-1 (Ta1) — Related Bulk Drug Substances
Regulatory assessment dated 15.11.2024 for the 04.12.2024 meeting; identification, US status, selected effectiveness and safety sections, and final conclusions were read; not an approval decision. Accessed: 03.11.2026.
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Randomised human trial; 17 January 2013; publication metadata and abstract reviewed · DOI: 10.1186/cc11932. Accessed: 3 November 2026.